These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 10085442)

  • 21. Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy.
    Andersen S; Jacobsen P; Tarnow L; Rossing P; Juhl TR; Parving HH
    Nephrol Dial Transplant; 2003 Feb; 18(2):293-7. PubMed ID: 12543883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-proteinuric effects of combination therapy with enalapril and losartan in patients with nephropathy due to type 2 diabetes.
    Cetinkaya R; Odabas AR; Selcuk Y
    Int J Clin Pract; 2004 May; 58(5):432-5. PubMed ID: 15206496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
    Titan SM; M Vieira J; Dominguez WV; Barros RT; Zatz R
    Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?
    Andersen S; Tarnow L; Cambien F; Rossing P; Juhl TR; Deinum J; Parving HH
    Kidney Int; 2002 Jul; 62(1):192-8. PubMed ID: 12081578
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels.
    Agarwal R; Siva S; Dunn SR; Sharma K
    Am J Kidney Dis; 2002 Mar; 39(3):486-92. PubMed ID: 11877567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G; Luño J; Barrio V; de Vinuesa SG; Praga M; Goicoechea M; Cachofeiro V; Nieto J; Fernández Vega F; Tato A; Gutierrez E;
    Am J Kidney Dis; 2013 Feb; 61(2):211-8. PubMed ID: 22939518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH; Baggen RG; Pauli S; Lindemans A; Vulto AG; Poldermans D; Boomsma F
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1.
    Amann B; Tinzmann R; Angelkort B
    Diabetes Care; 2003 Aug; 26(8):2421-5. PubMed ID: 12882873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteinuria-lowering effect of heparin therapy in diabetic nephropathy without affecting the renin-angiotensin-aldosterone system.
    Benck U; Haeckel S; Clorius JH; van der Woude FJ
    Clin J Am Soc Nephrol; 2007 Jan; 2(1):58-67. PubMed ID: 17699388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.
    Nakao N; Yoshimura A; Morita H; Takada M; Kayano T; Ideura T
    Lancet; 2003 Jan; 361(9352):117-24. PubMed ID: 12531578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beneficial effect of combination therapy with an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor on overt proteinuria in a patient with type 1 diabetic nephropathy.
    Kuriyama S; Tomonari H; Abe A; Imasawa T; Hosoya T
    Nephron; 2000 Dec; 86(4):529-30. PubMed ID: 11124615
    [No Abstract]   [Full Text] [Related]  

  • 39. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renoprotective effect of triple therapy with low-dose angiotensin receptor blocker, low-dose diuretic and Ca-antagonist in hypertensive type 2 diabetic patients with overt nephropathy].
    Kuriyama S; Tomonari H; Ohtsuka Y; Ohkido I; Hosoya T
    Nihon Jinzo Gakkai Shi; 2003; 45(4):367-71. PubMed ID: 12806973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.